Previous Close | 18.00 |
Open | 18.00 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 50.00 |
Expire Date | 2025-01-17 |
Day's Range | 18.00 - 18.00 |
Contract Range | N/A |
Volume | |
Open Interest | 84 |
Explore Gilead's latest financial performance and strategic directions, including updates on HIV, oncology, and liver disease segments.
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.